Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Gastrointestinal Cancer Share: Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me Forgot password? Click here
Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me